[CAS NO. 75438-57-2] Moxonidine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [75438-57-2]

Catalog

HY-B0374

Brand

MCE

CAS

75438-57-2

DESCRIPTION [75438-57-2]

Overview

MDL	MFCD00865794
Molecular Weight	241.68
Molecular Formula	C9H12ClN5O
SMILES	CC1=NC(OC)=C(NC2=NCCN2)C(Cl)=N1

For research use only. We do not sell to patients.

Summary

Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. Target: I1-R Moxonidine is a centrally acting antihypertensive agent. Mixed Nischarin (I1 imidazoline receptor) and α2-AR (adrenergic) agonist; displays 40-fold higher affinity for I1 receptors versus α2-adrenoceptors. Moxonidine reduced stimulated NE overflow (log EC50: -6.15 +/- 0.14). AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.01 +/- 0.25) [1]. The hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM. Furthermore, the noradrenergic innervation may be associated with a 42 kDa imidazoline receptor protein [2].

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04329806	Italo Biaggioni\|National Heart, Lung, and Blood Institute (NHLBI)\|Vanderbilt University Medical Center	Obesity-Associated Insulin Resistance	February 23, 2021	Phase 1
NCT04023565	Sergey V. Nedogoda\|Volgograd State Medical University	Arterial Hypertension\|Metabolic Syndrome	March 11, 2019	Phase 4
NCT01504321	Baker Heart and Diabetes Institute	Polycystic Ovary Syndrome	May 2012	Phase 4
NCT01791699	Spyridon Deftereos\|G.Gennimatas General Hospital	Atrial Fibrillation	August 2012	Phase 4
NCT01094769	Baker Heart and Diabetes Institute	Diabetic Nephropathies	April 2011	Phase 4
NCT05147753	Aristotle University Of Thessaloniki	Obesity\|Hypertension	January 11, 2010	Phase 4
NCT04050410	Vanderbilt University Medical Center\|National Heart, Lung, and Blood Institute (NHLBI)	Postural Tachycardia Syndrome	August 27, 2019	Early Phase 1
NCT01360710	Baker Heart and Diabetes Institute	Abdominal Obesity\|Hypertension	January 2012	Phase 4
NCT00244504	University Hospital, Basel, Switzerland	Cardiac Disease\|Vascular Surgery	November 2002	Phase 3
NCT01567124	Baker Heart and Diabetes Institute\|The Alfred\|Monash Medical Centre\|Ballarat Health Services	Schizophrenia	May 2012	Phase 4
NCT01180231	Baker Heart and Diabetes Institute	Obesity\|Overweight	September 2010	Phase 4
NCT00160277	Solvay Pharmaceuticals	Hypertension	July 2005	Phase 3
NCT00518479	University of Leeds\|The Leeds Teaching Hospitals NHS Trust	Hypertension\|Left Ventricular Hypertrophy	September 2003	Not Applicable
NCT02355821	National Research Center for Preventive Medicine\|National Medical Research Center for Therapy and Preventive Medicine	Osteopenia\|Arterial Hypertension	April 2015	Not Applicable
NCT01138423	UMC Utrecht\|Novartis Pharmaceuticals	Hypertension\|Abdominal Obesity\|Metabolic Syndrome	August 2010	Phase 4
NCT04474899	Royal Perth Hospital\|The University of Western Australia	Obesity\|Hypertension	June 24, 2015	Phase 4
NCT04479813	Royal Perth Hospital	Central Sympathetic Nervous System Diseases	July 8, 2015	Phase 4
NCT05312892	Vanderbilt University Medical Center	Obesity\|Hypertension	May 20, 2022	Phase 1\|Phase 2
NCT04140721	Vanderbilt University Medical Center\|National Heart, Lung, and Blood Institute (NHLBI)	Postural Tachycardia Syndrome	August 31, 2021	Early Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL ( 82.75 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.1377 mL	20.6885 mL	41.3770 mL
5 mM	0.8275 mL	4.1377 mL	8.2754 mL
10 mM	0.4138 mL	2.0689 mL	4.1377 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2 mg/mL (8.28 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-

4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine

BE 5895

Moxonidine

BDF 5895

2-(6-Chloro-4-methoxy-2-methylpyrimidin-5-ylamino)-2-imidazoline

Cynt

Lomox

Moxon

Normoxocin

Physiotens

LY 326869

Nucynt

Norcynt

Moxogamma

(4-Chloro-6-methoxy-2-methyl-pyrimidin-5-yl)-imidazolidin-2-ylidene-amine